567 related articles for article (PubMed ID: 33237994)
21. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
[TBL] [Abstract][Full Text] [Related]
22. A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions.
Marofi F; Rahman HS; Achmad MH; Sergeevna KN; Suksatan W; Abdelbasset WK; Mikhailova MV; Shomali N; Yazdanifar M; Hassanzadeh A; Ahmadi M; Motavalli R; Pathak Y; Izadi S; Jarahian M
Front Immunol; 2021; 12():681984. PubMed ID: 34248965
[TBL] [Abstract][Full Text] [Related]
23. Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.
Badar T; Shah NN
Curr Treat Options Oncol; 2020 Feb; 21(2):16. PubMed ID: 32025828
[TBL] [Abstract][Full Text] [Related]
24. [Immunotherapy with CAR-T cells in paediatric haematology-oncology].
Mirones I; Moreno L; Patiño-García A; Lizeaga G; Moraleda JM; Toribio ML; Pérez-Martínez A; ;
An Pediatr (Engl Ed); 2020 Jul; 93(1):59.e1-59.e10. PubMed ID: 32107177
[TBL] [Abstract][Full Text] [Related]
25. Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia.
Hashem Boroojerdi M; Rahbarizadeh F; Safarzadeh Kozani P; Kamali E; Safarzadeh Kozani P
Med Oncol; 2020 Oct; 37(11):100. PubMed ID: 33047234
[TBL] [Abstract][Full Text] [Related]
26. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
27. CAR-T Cell Therapies: An Overview of Clinical Studies Supporting Their Approved Use against Acute Lymphoblastic Leukemia and Large B-Cell Lymphomas.
Ahmad A; Uddin S; Steinhoff M
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486160
[TBL] [Abstract][Full Text] [Related]
28. The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.
Feinberg D; Paul B; Kang Y
Cell Immunol; 2019 Nov; 345():103964. PubMed ID: 31492448
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
30. Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy.
Ghassemi S; Milone MC
J Vis Exp; 2019 Dec; (154):. PubMed ID: 31904011
[TBL] [Abstract][Full Text] [Related]
31. Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients.
Wang Y; Li H; Song X; Qi K; Cheng H; Cao J; Shi M; Yan Z; Jing G; Pan B; Sang W; Wang X; Zhao K; Chen C; Chen W; Zheng J; Li Z; Xu K
Int J Lab Hematol; 2021 Apr; 43(2):250-258. PubMed ID: 33112046
[TBL] [Abstract][Full Text] [Related]
32. Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing.
Qayed M; McGuirk JP; Myers GD; Parameswaran V; Waller EK; Holman P; Rodrigues M; Clough LF; Willert J
Cytotherapy; 2022 Sep; 24(9):869-878. PubMed ID: 35718701
[TBL] [Abstract][Full Text] [Related]
33. Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments.
Xu X; Huang S; Xiao X; Sun Q; Liang X; Chen S; Zhao Z; Huo Z; Tu S; Li Y
Front Immunol; 2020; 11():569117. PubMed ID: 33643279
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of lymphoblastic leukemia with CD19-specific modified chimeric antigen receptor T cells].
Li HH; Zhu P; Wu XQ; Liu YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1753-6. PubMed ID: 25543510
[TBL] [Abstract][Full Text] [Related]
35. Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center.
Perica K; Curran KJ; Brentjens RJ; Giralt SA
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1135-1141. PubMed ID: 29499327
[TBL] [Abstract][Full Text] [Related]
36. The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies.
Cao JX; Gao WJ; You J; Wu LH; Liu JL; Wang ZX
Cytotherapy; 2019 Jul; 21(7):769-781. PubMed ID: 31160157
[TBL] [Abstract][Full Text] [Related]
37. Tisagenlecleucel in Acute Lymphoblastic Leukemia: A Review of the Literature and Practical Considerations.
Halford Z; Anderson MK; Bennett LL; Moody J
Ann Pharmacother; 2021 Apr; 55(4):466-479. PubMed ID: 32762363
[TBL] [Abstract][Full Text] [Related]
38. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
[TBL] [Abstract][Full Text] [Related]
39. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.
Luskin MR; DeAngelo DJ
Curr Hematol Malig Rep; 2017 Aug; 12(4):370-379. PubMed ID: 28656487
[TBL] [Abstract][Full Text] [Related]
40. Effect of transplant status in CD19-targeted CAR T-cell therapy: a systematic review and meta-analysis.
Nagle K; Tafuto B; Palladino Kim L; Parrott JS
Med Oncol; 2018 Sep; 35(11):144. PubMed ID: 30206753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
